Онкогематология (Jul 2014)

Herpes zoster in multiple myeloma patients during bortezomib treatment

  • I. N. Nazarova,
  • M. N. Protasova,
  • N. A. Nikishina

DOI
https://doi.org/10.17650/1818-8346-2011-6-3-35-38
Journal volume & issue
Vol. 6, no. 3
pp. 35 – 38

Abstract

Read online

Recent advances in multiple myeloma (MM) treatment associated with new drug use including bortezomib. Experiences in wide ambul atory drug use confirm therapy success for this serious disease, but at the same time reveals the most common side effects. One of th e most significant is the reactivation of Herpes zoster , which leads to decrease MM therapy results because of inability to perform standard therapy in these patients. Literature data and own experiences about reactivation of Herpes zoster during bortezomib therapy as monothe rapy and in combination, which varies from 7 to 34% according to different authors and 25% of own experiences, is presented. Treatment and preventive schedule of this complication are shown.

Keywords